Argenx Se (ARGX) Non-Current Deffered Revenue (2016 - 2021)

Argenx Se's (ARGX) quarterly Non-Current Deffered Revenue came in at -$269.0 million in Q4 2021, down 202.92% YoY from $261.4 million in Q4 2020, and little changed on a QoQ basis from -$269.0 million in Q2 2021.

Argenx Se (ARGX) Non-Current Deffered Revenue (2016 - 2021) Analysis & Trends

Argenx Se (ARGX) has 6 years of Non-Current Deffered Revenue data on file, last reported at -$269.0 million in Q4 2021.

  • Quarterly Non-Current Deffered Revenue fell 202.92% year-over-year to -$269.0 million in Q4 2021, while the trailing twelve-month figure through Dec 2021 was -$269.0 million (down 202.92% YoY) and the FY2021 annual result came in at -$269.0 million, down 200.0% from the prior year.
  • Non-Current Deffered Revenue held at -$269.0 million in Q4 2021, from -$269.0 million in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $267.1 million in Q2 2019 to a low of -$269.0 million in Q2 2021.
  • A 5-year average of $26.8 million and a median of $25855.9 in 2018 frame the typical range for Non-Current Deffered Revenue.
  • Annual changes were most pronounced in 2019 — Non-Current Deffered Revenue jumped 14834.5% — and 2021, when it tumbled 1477.94%.
  • Tracing ARGX's Non-Current Deffered Revenue over 5 years: stood at $1.7 million in 2017, then tumbled by 196.94% to -$1.6 million in 2018, then jumped by 14834.5% to $241.3 million in 2019, then climbed by 8.32% to $261.4 million in 2020, then slumped by 202.92% to -$269.0 million in 2021.
  • The last three Non-Current Deffered Revenue figures came in at -$269.0 million (Q4 2021), -$269.0 million (Q2 2021), and $261.4 million (Q4 2020), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Deffered Revenue (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 220.40 Mn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn -
4 Revolution Medicines 43.64 Bn 43.64 Bn - -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn -
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn -
7 Royalty Pharma 33.72 Bn 35.84 Bn - -
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn -
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn -
10 Roivant Sciences 26.16 Bn 26.85 Bn 1.16 Mn -

Historic Data

Download Data
DateValue
Dec 31, 2021 -269.04 Mn
Jun 30, 2021 -269.04 Mn
Dec 31, 2020 261.41 Mn
Jun 30, 2020 -17.05 Mn
Dec 31, 2019 241.34 Mn
Jun 30, 2019 267.05 Mn
Dec 31, 2018 -1.64 Mn
Dec 31, 2017 1.69 Mn
Dec 31, 2016 10.87 Mn